Which country is Pembrolizumab produced in?

The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s anti-PD-1 therapy Pembrolizumab in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (combined positive score [CPS] ≥1) as determined by an FDA-approved test.

Pembrolizumab is an anti-programmed death receptor-1 (PD-1) therapy that improves the body's immune system's ability to help detect and fight tumor cells. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes that may affect tumor cells and healthy cells. The approval of pembrolizumab was based on the phase 3 KEYNOTE-826 trial, which evaluated pembrolizumab plus chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin), with or without bevacizumab, compared with the same chemotherapy regimen.

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around 15,000 yuan. This drug is a strictly controlled drug. It is not yet included in the medical insurance and is an imported drug. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.